ARTICLE | Company News
Orion, Pharmacia anxiety deal
August 27, 2001 7:00 AM UTC
Orion (Espoo, Finland) and PHA will develop Orion's deramciclane 5-HT 2A and 2C receptor antagonist, which is in European Phase III testing to treat generalized anxiety disorder. Orion will fund U.S. ...